Last reviewed · How we verify
Dibazol — Competitive Intelligence Brief
phase 2
bendazol
Cardiovascular
Small molecule
Live · refreshed every 30 min
Target snapshot
Dibazol (BENDAZOL). Dibazol works by interacting with a specific biological target to produce a therapeutic effect.
Comparator set (3 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Dibazol TARGET | BENDAZOL | phase 2 | bendazol | |||
| Ricobendazole | albendazole sulfoxide | marketed | albendazole sulfoxide | Tubulin alpha chain | ||
| Febendazole | FENBENDAZOLE | marketed | fenbendazole | Mitogen-activated protein kinase 14, Beta-lactamase 1 | ||
| Flumoxane | FLUBENDAZOLE | marketed | flubendazole |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (bendazol class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Dibazol CI watch — RSS
- Dibazol CI watch — Atom
- Dibazol CI watch — JSON
- Dibazol alone — RSS
- Whole bendazol class — RSS
Cite this brief
Drug Landscape (2026). Dibazol — Competitive Intelligence Brief. https://druglandscape.com/ci/bendazol. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing